NCT05000372 is a Phase 1, PHASE2 clinical trial of 68Ga-grazytracer in Cancer, sponsored by Peking University Cancer Hospital & Institute.

Who is sponsoring NCT05000372?

NCT05000372 is sponsored by Peking University Cancer Hospital & Institute.

What drugs are being tested in NCT05000372?

Interventions in NCT05000372: 68Ga-grazytracer.

Is NCT05000372 still recruiting?

NCT05000372 is currently completed. Last updated 4 December 2024.

Last reviewed 2024-12-04 · How we verify

NCT05000372

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

68Ga-grazytracer PET/CT of Tumor Responses to Immunotherapy

Completed Phase 1, PHASE2 Last updated 4 December 2024

What this trial tests

Phase 1, PHASE2 trial testing 68Ga-grazytracer in Cancer in 24 participants. Completed in 31 May 2024.

Timeline

22 September 2021

Primary endpoint
25 May 2024

31 May 2024

Quick facts

Lead sponsor	Peking University Cancer Hospital & Institute
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	diagnostic
Enrollment	24
Start date	22 September 2021
Primary completion	25 May 2024
Estimated completion	31 May 2024
Sites	1 location across China

Drugs / interventions tested

68Ga-grazytracer — full drug profile →

Conditions studied

Cancer — all drugs for Cancer →

Sponsor

Peking University Cancer Hospital & Institute

Who can join

Adults 18 to 75, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the safety and clinical predictive value of 68Ga-grazytracer in subjects with solid tumor or lymphoma receiving immunotherapy.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Noninvasive interrogation of CD8+ T cell effector function for monitoring early tumor responses to immunotherapy.
Zhou H, Wang Y, Xu H, Shen X, et al · · 2022 · cited 49× · PMID 35788116 · DOI 10.1172/jci161065
Molecular imaging to support cancer immunotherapy.
van de Donk PP, Oosting SF, Knapen DG, van der Wekken AJ, et al · · 2022 · cited 30× · PMID 35922089 · DOI 10.1136/jitc-2022-004949
<sup>68</sup>Ga-grazytracer PET for noninvasive assessment of response to immunotherapy in solid tumors and lymphomas: a phase 1/2 clinical trial.
Shen X, Zhou H, Zhou X, Liu Z, et al · · 2024 · cited 13× · PMID 39389969 · DOI 10.1038/s41467-024-53197-2
Clinical Application of ImmunoPET Targeting Checkpoint Inhibitors.
Abenavoli EM, Linguanti F, Calabretta R, Delgado Bolton RC, et al · · 2023 · cited 11× · PMID 38067379 · DOI 10.3390/cancers15235675
The role of CD8 PET imaging in guiding cancer immunotherapy.
Zhang J, Du B, Wang Y, Cui Y, et al · · 2024 · cited 8× · PMID 39072335 · DOI 10.3389/fimmu.2024.1428541
Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions.
Wu Y, Xue R, Luo X, Liao J, et al · · 2026 · PMID 41777248 · DOI 10.1002/mco2.70638
The application and prospect of granzyme B-targeted PET imaging in cancer immunotherapy.
Tong X, Jiang Y, Bi N. · · 2025 · PMID 41361310 · DOI 10.1186/s12967-025-07419-w

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Other Peking University Cancer Hospital & Institute trials

Trials by the same sponsor.

NCT07527806 — Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Im · Phase 2 · not yet recruiting
NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
NCT07417241 — SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study · Phase 2 · not yet recruiting
NCT07470203 — Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer · not yet recruiting
NCT07394192 — Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-I · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05000372 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University Cancer Hospital & Institute
Last refreshed: 4 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05000372.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing